Research programme: neurodegenerative diseases - Exelixis
Latest Information Update: 20 Jun 2006
At a glance
- Originator Exelixis
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 20 Jun 2006 No development reported - Preclinical for Alzheimer's disease in USA (unspecified route)
- 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
- 27 Sep 2002 Preclinical trials in Alzheimer's disease in USA (unspecified route)